


NCC Japan joins Illuminox Alliance Institutes network

02 June 2020 | News

NCC and Rakuten Medical will pursue multiple avenues to advance Illuminox-based cancer therapies



US based Rakuten Medical, Inc., a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox[™] technology platform, established a strategic cancer research alliance network, the Illuminox Alliance Institutes (IAI), in order to advance the development of new cancer therapies.

The National Cancer Center Japan (NCC) signed a memorandum of understanding (MOU) to become the first institution to join the IAI network. Rakuten Medical will expand the IAI network to include premier cancer centers from around the world.

NCC is currently conducting clinical trials with ASP-1929, Rakuten Medical's first investigational drug developed on the Illuminox platform.

Under the signed MOU, NCC and Rakuten Medical will pursue multiple avenues to advance Illuminox-based cancer therapies. NCC will designate a lead principal who will act as an Illuminox Advisor.

The Illuminox Advisor will, based on their expertise, actively participate in various research plans and Advisory board meetings, support identification of additional investigators from the IAI and assist with education and training related to the use of Illuminox platform therapies.